Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIL116 in Healthy Participants and Patients With IgA Nephropathy
NCT07375758Phase 2Recruiting
- Sponsor
- Beijing Tianguangshi Pharmaceutical Technology
- Start
- Feb 2026
- Primary completion
- Jun 2028
- Modality
- Antibody Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of CLYM116 in IgA nephropathy (IgAN), sponsored by Beijing Tianguangshi Pharmaceutical Technology. Started Feb 2026; status: recruiting.
02
Drugs
CLYM116
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07375758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07375758.